The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Interleukin-2 Therapy in Patients with HIV Infection
Open accessAbstract
BACKGROUND: Used in combination with antiretroviral therapy, subcutaneous recombinant interleukin-2 raises CD4+ cell counts more than does antiretroviral therapy alone. The clinical implication of these increases is not known. METHODS: We conducted two trials: the Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy (SILCAAT) study and the Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT). In each, patients infected with the human immunodeficiency virus (HIV) who had CD4+ cell counts of either 50 to 299 per cubic millimeter (SILCAAT) or 300 or more per cubic millimeter (ESPRIT) were randomly assigned to receive interleukin-2 plus antiretroviral therapy or antiretroviral therapy alone. The interleukin-2 regimen consisted of cycles of 5 consecutive days each, administered at 8-week intervals. The SILCAAT study involved six cycles and a dose of 4.5 million IU of interleukin-2 twice daily; ESPRIT involved three cycles and a dose of 7.5 million IU twice daily. Additional cycles were recommended to maintain the CD4+ cell count above predefined target levels. The primary end point of both studies was opportunistic disease or death from any cause. RESULTS: In the SILCAAT study, 1695 patients (849 receiving interleukin-2 plus antiretroviral therapy and 846 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 202 cells per cubic millimeter were enrolled; in ESPRIT, 4111 patients (2071 receiving interleukin-2 plus antiretroviral therapy and 2040 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 457 cells per cubic millimeter were enrolled. Over a median follow-up period of 7 to 8 years, the CD4+ cell count was higher in the interleukin-2 group than in the group receiving antiretroviral therapy alone--by 53 and 159 cells per cubic millimeter, on average, in the SILCAAT study and ESPRIT, respectively. Hazard ratios for opportunistic disease or death from any cause with interleukin-2 plus antiretroviral therapy (vs. antiretroviral therapy alone) were 0.91 (95% confidence interval [CI], 0.70 to 1.18; P=0.47) in the SILCAAT study and 0.94 (95% CI, 0.75 to 1.16; P=0.55) in ESPRIT. The hazard ratios for death from any cause and for grade 4 clinical events were 1.06 (P=0.73) and 1.10 (P=0.35), respectively, in the SILCAAT study and 0.90 (P=0.42) and 1.23 (P=0.003), respectively, in ESPRIT. CONCLUSIONS: Despite a substantial and sustained increase in the CD4+ cell count, as compared with antiretroviral therapy alone, interleukin-2 plus antiretroviral therapy yielded no clinical benefit in either study. (ClinicalTrials.gov numbers, NCT00004978 [ESPRIT] and NCT00013611 [SILCAAT study].)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
The Statistical Analysis of Failure Time Data
Kalbfleisch, J. D., & Prentice, R. L. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781118032985 · Cited by 3,219
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
Kuller, L. H., Tracy, R., Belloso, W., Wit, S. D., Drummond, F., Lane, H. C., Ledergerber, B., Lundgren, J., Neuhaus, J., Nixon, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050203 · Cited by 1,617
Clarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M., & Peto, R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010013 · Cited by 877
Composite Outcomes in Randomized Trials: Greater Precision But With Greater Uncertainty?
Freemantle, N., Calvert, M., Wood, J., Eastaugh, J., & Griffin, C. (2003) · JAMA · doi:10.1001/jama.289.19.2554 · Cited by 783
Kovacs, J. A., Baseler, M., Dewar, R. J., Vogel, S., Davey, R. T., Falloon, J., Polis, M. A., Walker, R. E., Stevens, R., Salzman, N. P., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320904 · Cited by 425
Kovacs, J. A., Vogel, S., Albert, J. M., Falloon, J., Davey, R. T., Walker, R. E., Polis, M. A., Spooner, K., Metcalf, J. A., Baseler, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610313351803 · Cited by 402
Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatment
Levy, Y., Lacabaratz, C., Weiss, L., Viard, J.-P., Goujard, C., Lelièvre, J.-D., Boué, F., Molina, J.-M., Rouzioux, C., Avettand-Fénoêl, V., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38052 · Cited by 381
Girardi, E., Sabin, C. A., & Monforte, A. D. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000286597.57066.2b · Cited by 350
Lewden, C., May, T., Rosenthal, E., Burty, C., Bonnet, F., Costagliola, D., Jougla, E., Semaille, C., Morlat, P., Salmon, D., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31817efb54 · Cited by 342
The role of HIV in serious diseases other than AIDS.
Phillips, A. N., Neaton, J., & Lundgren, J. D. (2008) · AIDS · doi:10.1097/qad.0b013e3283174636 · Cited by 269
Ovacs, J. O. A. K., Ogel, S. U. V., Lbert, M. A., et al. (1996) · Cited by 210
Kovacs, J. A., Lempicki, R. A., Sidorov, I. A., Adelsberger, J. W., Sereti, I., Sachau, W., Kelly, G., Metcalf, J. A., Davey, R. T., Falloon, J., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23196 · Cited by 127
Emery, S., Capra, W. B., Cooper, D. A., Mitsuyasu, R. T., Kovacs, J. A., Vig, P., Smolskis, M. C., Saravolatz, L. D., Lane, H. C., Fyfe, G., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/315736 · Cited by 103
Carr, A. D., Emery, S., Lloyd, A. R., Hoy, J., Garsia, R. J., French, M. A., Stewart, G. J., Fyfe, G., Cooper, D. A., & Australian IL‐2 Study Group (1998) · The Journal of Infectious Diseases · doi:10.1086/515653 · Cited by 92
Sereti, I., Anthony, K. B., Martinez-Wilson, H. F., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4355 · Cited by 88
The Evaluation of Subcutaneous Proleukin® (interleukin-2) in a Randomized International Trial
Emery, S., Abrams, D. I., Cooper, D. A., Darbyshire, J. H., Lane, H. C., Lundgren, J. D., & Neaton, J. D. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(01)00179-9 · Cited by 81
CD4 cell count as a surrogate endpoint in HIV clinical trials
Hughes, M. D., Daniels, M. J., Fischl, M. A., Kim, S., & Schooley, R. T. (1998) · AIDS · doi:10.1097/00002030-199814000-00014 · Cited by 75
Abrams, D. I., Bebchuk, J. D., Denning, E. T., Davey, R. T., Fox, L. M., Lane, H. C., Sampson, J. H., Verheggen, R., Zeh, D., & Markowitz, N. P. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200203010-00002 · Cited by 44
Cited by
Murray, D. D., Suzuki, K., Law, M., Trebicka, J., Neuhaus, J., Wentworth, D., Johnson, M., Vjecha, M. J., Kelleher, A. D., Emery, S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139981 · Cited by 2,740
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
The end of AIDS: HIV infection as a chronic disease
Deeks, S. G., Lewin, S. R., & Havlir, D. V. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61809-7 · Cited by 2,063
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-15
- Volume
- 361
- Issue
- 16
- Pages
- 1548-1559
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167148984
- Cited by
- 381
- References
- 20
- FWCI
- 17.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.